Reata Pharmaceuticals Inc. Class A (RETA)
$172.36
$0.00 (0.00%)As on 26-Sep-2023 09:30EDT
Market cap
$6,566 Mln
Revenue (TTM)
$24 Mln
P/E Ratio
--
P/B Ratio
285.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-281 Mln
-
ROE
-1.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.7
-
Debt to Equity
0.8
-
Book Value
$--
-
EPS
$-2.8
-
Face value
--
-
Shares outstanding
33,587,600
10 Years Aggregate
CFO
$-1,401.95 Mln
EBITDA
$-1,151.29 Mln
Net Profit
$-1,317.52 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Reata Pharmaceuticals Inc. Class A (RETA)
| 353.7 | 2.0 | 83.8 | 679.2 | 22.5 | 14.8 | -- |
|
BSE Sensex*
| -11.1 | -2.1 | -8.9 | -7.5 | 6.6 | 9.1 | 11.4 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|
|
Reata Pharmaceuticals Inc. Class A (RETA)
| 44.1 | -78.7 | -39.5 | 264.4 | 97.4 | 29.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Reata Pharmaceuticals Inc. Class A (RETA)
|
172.4 | 6,566.5 | 24.4 | -80.1 | -1,368.2 | -- | -- | 285.9 |
| 79.7 | 10,950.2 | 622.0 | -300.9 | -7.4 | -62.9 | -- | 16.7 | |
| 78.6 | 10,123.1 | 105.8 | -829.6 | -718.2 | -- | -- | 60.3 | |
| 51.1 | 12,494.9 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.5 | 6.3 | |
| 98.7 | 12,823.7 | 1,080.2 | -433.2 | -29.6 | -- | -- | 55.7 | |
| 8.2 | 8,494.0 | 141.0 | -854.5 | -97.9 | -- | -- | 0.0 | |
| 316.3 | 9,223.6 | 417.3 | 225.0 | 42.8 | 18.6 | 41.8 | 7.1 | |
| 539.9 | 11,459.4 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 21.6 | |
| 419.2 | 11,917.7 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.2 | 20.2 | |
| 345.5 | 9,250.5 | 0.0 | -326.5 | -- | -37.2 | -- | 6.5 |
Shareholding Pattern
View DetailsAbout Reata Pharmaceuticals Inc. Class A (RETA)
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs,... including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. As of September 26, 2023, Reata Pharmaceuticals, Inc. operates as a subsidiary of Biogen Inc. Read more
-
Chairman & CEO
Mr. J. Warren Huff
-
Chairman & CEO
Mr. J. Warren Huff
-
Headquarters
Plano, TX
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Reata Pharmaceuticals Inc. Class A (RETA)
What is the current share price of Reata Pharmaceuticals Inc Class A (RETA) Today?
The share price of Reata Pharmaceuticals Inc Class A (RETA) is $172.36 (NASDAQ) as of 26-Sep-2023 09:30 EDT. Reata Pharmaceuticals Inc Class A (RETA) has given a return of 22.47% in the last 3 years.
What is the current PB & PE ratio of Reata Pharmaceuticals Inc Class A (RETA)?
Since, TTM earnings of Reata Pharmaceuticals Inc Class A (RETA) is negative, P/E ratio is not available.
The P/B ratio of Reata Pharmaceuticals Inc Class A (RETA) is 285.94 times as on 26-Sep-2023, a 6268 premium to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-4.42
|
-21.00
|
|
2021
|
-3.23
|
-0.76
|
|
2020
|
-17.28
|
-4.47
|
|
2019
|
-22.28
|
-9.10
|
|
2018
|
-20.70
|
-3.97
|
What is the 52 Week High and Low of Reata Pharmaceuticals Inc Class A (RETA)?
The 52-week high and low of Reata Pharmaceuticals Inc Class A (RETA) are Rs -- and Rs -- as of 15-May-2026.
What is the market cap of Reata Pharmaceuticals Inc Class A (RETA)?
Reata Pharmaceuticals Inc Class A (RETA) has a market capitalisation of $ 6,566 Mln as on 26-Sep-2023. As per SEBI classification, it is a company.
Should I invest in Reata Pharmaceuticals Inc Class A (RETA)?
Before investing in Reata Pharmaceuticals Inc Class A (RETA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.